Idiopathic Pulmonary Fibrosis

November 22, 2017November 22, 2017

PF Foundation Summit Highlights Roles of Care, Research, and Technology

The Pulmonary Fibrosis Foundation’s PFF Summit 2017 Nov. 9-11 in Nashville, Tennessee, recorded an unprecedented number of attendees, including physicians, researchers, patients, caregivers and industry professionals. The lung disease summit takes place ... Read more

November 21, 2017November 21, 2017

Many European IPF Patients Are Not Receiving Anti-lung-scarring Therapies, Survey Indicates

Idiopathic Pulmonary Fibrosis, News

Despite anti-fibrotic therapies’ ability to help idiopathic pulmonary fibrosis patients, more than half of Europeans who have the disease are not receiving them. That’s because a lot fo physicians are ... Read more

November 17, 2017November 17, 2017

Veracyte’s Genomic Tool Aids in Diagnosing IPF Without Surgery, Real-world Data Suggests

Idiopathic Pulmonary Fibrosis

Veracyte presented early data from a real-world clinical test showing that its Envisia Genomic Classifier is an efficient tool for diagnosing idiopathic pulmonary fibrosis (IPF) without invasive and expensive surgery. ... Read more

November 16, 2017November 16, 2017

Ofev Slows Scarring in Pulmonary Fibrosis Patients’ Lungs, Phase 3b Trial Shows

Idiopathic Pulmonary Fibrosis, News

Boehringer Ingelheim’s Ofev (nintedanib) slows scarring in idiopathic pulmonary fibrosis patients’ lungs, a Phase 3b trial indicates. The company used an imaging technique to check on Ofev’s anti-fibrotic properties. It was the ... Read more

November 14, 2017November 14, 2017

ATS Foundation, Boehringer Ingelheim Fund New Fellowship on IPF Research

Idiopathic Pulmonary Fibrosis, News

The American Thoracic Society (ATS) Foundation and Boehringer Ingelheim have jointly launched a new research fellowship in idiopathic pulmonary fibrosis (IPF), aiming to grant young investigators $100,000 over a two-year period from ... Read more

November 13, 2017November 13, 2017

Esbriet Safe but Less Effective in Severe IPF Patients After 6 Months of Treatment, Small Study Says

Idiopathic Pulmonary Fibrosis, News

A retrospective real-world study found that the benefits of Esbriet (pirfenidone) in people with advanced idiopathic pulmonary fibrosis (IPF) appeared to diminish after six months of treatment, although side effects were ... Read more

November 9, 2017November 9, 2017

Esbriet Treatment Helps Reduce Cough in IPF Patients, European Study Shows

Idiopathic Pulmonary Fibrosis, News

Treatment with Esbriet (pirfenidone) significantly reduced cough by 34 percent in patients with idiopathic pulmonary fibrosis (IPF), along with cough severity, a new 12-week study shows. The study, “Effect of pirfenidone ... Read more

November 7, 2017November 7, 2017

Cancer Factor Has Potential as Lung Fibrosis Treatment Target, Chinese Study Finds

Idiopathic Pulmonary Fibrosis, News

A factor that causes cancer may actually help prevent pulmonary fibrosis, researchers at China’s Jilin Provincial Cancer Hospital say. The protein, called TIAM1, is found in higher levels in mouse models ... Read more

November 1, 2017November 1, 2017

Prometic’s Pulmonary Fibrosis Therapy PBI-4050 Earns FDA Fast Track Status

Idiopathic Pulmonary Fibrosis

The U.S. Food and Drug and Drug Administration has awarded Fast Track status to PBI-4050, Prometic Life Sciences‘ treatment for lung scarring in idiopathic pulmonary fibrosis. The Fast Track designation ... Read more

October 27, 2017October 27, 2017

Scientists Identify Another Gene Variation Associated with Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

Scientists have identified a variation of a gene that they say makes a person susceptible to developing idiopathic pulmonary fibrosis. The discovery raises the possibility of developing an IPF therapy that ... Read more